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Athrombospondin-related anonymous protein (TRAP) of the human malaria parasite Plasmodium falcipa-
rum shares highly conserved amino acid sequence motifs with the circumsporozoite protein of all plasmodia
sequenced so far, as well as with unrelated proteins like thrombospondin and properdin. Although it was first
described as an asexual blood stages protein, there has been some controversy about its expression in these
stages. Pursuant to our interest in the conserved sequences within the malaria antigens, we synthesized an
18-residue peptide (18-mer) representing a conserved motif of TRAP and raised polyclonal antibodies against
it. In an immunoblot assay in which we probed proteins from the asexual blood stages of the parasite, we found
that this antibody recognized predominantly a 78-kDa protein in the whole parasite lysate. Furthermore, in
another immunoblot, the recombinant TRAP constructs containing the conserved-motif sequence were dis-
tinctly recognized by the antipeptide antibodies, whereas a construct lacking the motif sequence was not,
suggesting that the antibodies specifically cross-reacted with a protein which might be a TRAP-like protein
present in the asexual blood stages of the parasite. Also, in an immunofluorescence assay, this antibody
brightly stained the acetone-fixed trophozoites of the parasite. Most significantly, anti-18-mer immunoglobulin
G, as well as antipeptide antibody against a smaller (nonamer) construct representing the most conserved
motif within the 18-mer, inhibited the merozoite invasion of erythrocytes in a dose-dependent manner. These
results provide evidence of the expression of TRAP or a TRAP-like protein in the asexual blood stages of the
parasite and of a possible role of the conserved motifs in the parasite-host cell interaction during the process
of invasion.
The human malaria parasite Plasmodium falciparum follows
a complex life cycle which involves distinctly different devel-
opmental stages. A number of different antigens are expressed
at particular stages; some of these are believed to play a role in
specific invasion processes involving the parasite and the host
cells. Thus, there has been considerable interest in proteins
such as the circumsporozoite (CS) protein and the major mer-
ozoite surface proteins, MSP-1 and MSP-2, in connection with
the search for suitable vaccine candidates (13, 16, 26, 32).
However, extensive polymorphism in these and most other
malarial antigens is a major concern in the development of a
malaria vaccine based on whole antigens (14, 17, 24).
A P. falciparum protein described as thrombospondin-re-
lated anonymous or adhesive protein (TRAP) shares amino
acid sequence motifs with region II of the CS protein of all
Plasmodium species sequenced so far (15, 27, 29). There is a
cluster of cysteine residues in and around the conserved se-
quence suggestive of a secondary structure. A Plasmodium
yoelii analog of TRAP, the sporozoite surface protein-2 (SSP-
2), has also been shown to contain the same conserved motifs
(30, 31). Interestingly, these motifs are present in a variety of
other different proteins of biological significance, such as
thrombospondin (hence, the name TRAP), properdin, and
terminal components of the complement pathway (15, 27, 29).
An antigenic protein from Eimeria tenella, a parasite phyloge-
netically related to Plasmodium spp., also contains these con-
served motifs (9). The nonapeptide WSPCSVTCG, which rep-
resents the most homologous sequence of the conserved
motifs, is present in three copies in thrombospondin, six copies
in properdin, and one copy each in the CS proteins of six
species of malaria parasite (27).
The occurrence in the sporozoite and, possibly, in the asex-
ual blood stages of P. falciparum of a highly conserved se-
quence which is also present in thrombospondin and properdin
led to the speculation that TRAP may be a functionally rele-
vant protein and that the conserved motifs may be involved in
the parasite’s interaction with the host cell membrane. In fact,
two laboratories have provided data to indicate that synthetic
CS protein constructs or recombinant TRAP constructs con-
taining a conserved nine-residue motif indeed bind to hepato-
cytes and can competitively inhibit sporozoite invasion of
HepG2 cells (4, 25). Recently, we have demonstrated that
immunization of mice with a synthetic CS peptide, a 32-residue
construct containing this conserved motif, could protect them
against live challenge with a lethal inoculum of Plasmodium
berghei sporozoites (6).
If a TRAP-like molecule is indeed involved in the recogni-* Corresponding author.
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tion of a receptor molecule on the erythrocyte surface, then it
may well be an attractive target for interference with the asex-
ual erythrocytic cycle of the parasite. It was thus appealing to
probe whether the most conserved motif is in some way in-
volved in the interaction of the parasite with the host erythro-
cyte. We have synthesized peptides corresponding to the con-
served motifs (18-mer) and the most homologous nonapeptide
sequence within these motifs and present evidence that anti-
bodies to these peptides recognize predominantly a 78-kDa
protein in the asexual erythrocytic stages (trophozoites) of P.
falciparum and also inhibit merozoite invasion of erythrocytes
in a dose-dependent manner.
MATERIALS AND METHODS
Parasite. The FID-3 strain of P. falciparum, isolated from a patient in New
Delhi in the year 1987 and subsequently maintained in continuous in vitro culture
by the candle jar method of Trager and Jensen (36), was used in this study. For
making the whole parasite protein lysate, a preparation rich in trophozoite- and
schizont-infected erythrocytes was first obtained by centrifugation of cultures
showing high-level parasitemia (;7%) and a preponderance of trophozoites and
schizonts on a Histopaque-1077(R) (Sigma Chemical Co., St. Louis, Mo.) density
gradient. This parasite-rich preparation was washed with plain RPMI-1640 me-
dium, i.e., medium without serum but containing 25 mM HEPES (N-2-hydroxy-
ethylpiperazine-N9-2-ethanesulfonic acid) and 0.2% sodium bicarbonate, and
subjected to hemolysis with 0.2% saponin in 0.85% NaCl solution at 48C. The
liberated parasites were extensively washed with chilled phosphate-buffered sa-
line (PBS) (0.15 M, pH 7.2) to get rid of hemoglobin, and the erythrocyte
membranes were separated from the lysate by centrifugation. Extraction of the
sedimented parasites with 5 volumes of the chilled extraction buffer (50 mM
Tris-HCl, 5 mM EDTA [pH 8.0], 0.5% Triton X-100, 10 mM chymostatin, 1 mM
phenylmethylsulfonyl fluoride, 10 mM pepstatin, and 10 mM leupeptin) was
followed by ultrasonication in an ice bath. Finally, the preparation was centri-
fuged at 14,000 rpm at 48C, and the supernatant was used as the whole parasite
lysate in the enzyme-linked immunosorbent assay (ELISA) or the immunoblot-
ting assay.
Synthetic peptides. An 18-residue peptide representing the conserved motifs
(249EWSPCSVTCGKGTRSRKR266) of TRAP was synthesized by stepwise sol-
id-phase peptide synthesis with phenylacetamidomethyl resin on a manual syn-
thesizer. The peptide was simultaneously deprotected and cleaved with triflu-
oromethanesulfonic acid in the presence of thioanisole and 1,2-ethanedithiol.
The crude peptide was extracted in 20% acetic acid, lyophilized, and purified by
high-pressure liquid chromatography (HPLC) on an aquapore C-8 column (100
by 10 mm; Applied Biosystems). Purified peptide was characterized by amino
acid analysis and analytical reverse-phase HPLC on a C-18 column (Waters).
This construct was readily soluble in water as well as in PBS, pH 7.2, and could
be used in the parasite growth inhibition assays described below. An analog of
the 18-mer, with the 2SH side chain of cysteine residues kept protected with a
tertiary butyl group, was synthesized by Fmoc (fluorenylmethoxyucarbonyl)
chemistry.
A nonapeptide, representing the most conserved sequence (250WSPCS-
VTCG258) within the 18-mer, was also synthesized and purified in the same
manner as described above. The nonapeptide, however, was only sparingly sol-
uble in water and required 20% acetic acid for its dissolution, rendering it
unsuitable for use in the parasite growth inhibition assays.
Another P. falciparum peptide, a 21-residue construct representing a con-
served region of MSP-1 and described as P-8 in our previous work (21, 33), was
also included in this study for comparison.
Recombinant TRAP constructs. Small amounts of a series of nested recom-
binant constructs representing portions of TRAP containing the conserved-motif
sequence or its adjacent sequences were a kind gift from Andrea Crisanti of the
University of Rome, Rome, Italy. A detailed description of the procedures
employed to obtain and characterize these constructs has been published by
Muller and colleagues (25). Specifically, these constructs spanned almost the
entire length of the protein (TRAP 1), from residue 26 to 393 (TRAP 1.1), 26 to
376 (TRAP 1.2), 26 to 299 (TRAP 1.3), 26 to 273 (TRAP 1.4), and 26 to 204
(TRAP 1.5).
Immunization with peptides. Rabbits (New Zealand White) used in this study
were procured from the Small Animal Facility of the National Institute of
Immunology, New Delhi, India. The animals were housed, fed, and handled in
experimental manipulations in accordance with the recommendations made by
the National Institutes of Health (Guide for the Care and Use of Laboratory
Animals).
We found that immunization of rabbits with carrier-free 18-mer or nonapep-
tide did not induce any detectable specific antibody response, as monitored by
ELISA (unpublished results). These peptides were, therefore, conjugated to a
carrier protein for the purpose of immunizing animals. The 18-mer was coupled
to tetanus toxoid (TT) by using m-maleimidobenzoyl-N-hydroxysuccinimide es-
ter as the conjugating reagent (21), while conjugation of the nonapeptide with
bovine serum albumin (BSA) was accomplished by using glutaraldehyde as the
coupling reagent (19).
Rabbits were immunized with the 18-mer–TT conjugate (250 mg per animal)
emulsified in complete Freund’s adjuvant (CFA) and inoculated subcutaneously
at multiple sites; they were boosted on day 28 with a similar amount of the same
immunogen mixed with incomplete Freund’s adjuvant (IFA). Samples of rabbit
serum were obtained on days 0, 14, 28, 42, and 56 and assayed for the presence
of peptide-specific antibody in an ELISA with carrier-free 18-mer as the capture
antigen. The preimmune and test sera were adsorbed with fresh, normal human
erythrocytes as well as with Escherichia coli bacterial lysate before they were used
to test for cross-reactivity with the parasite lysate and various recombinant
TRAP constructs in the ELISA and immunoblotting assays.
Another group of two rabbits was immunized and boosted with the nonapep-
tide-BSA conjugate in a similar fashion following an identical schedule. Sera
collected on days 0, 14, 28, 42, and 56 were tested for the peptide-specific
antibody in an ELISA with nonapeptide-TT conjugate as the capture antigen.
Serum samples from a rabbit making a high-level antibody response to the P-8
P. falciparum MSP-1 peptide and from a rabbit immunized with the whole
parasite lysate were also included in certain experiments as described below. All
sera were adsorbed with normal human erythrocytes and E. coli bacterial lysate,
as mentioned above, to remove heterophile antibodies.
In some experiments, purified immunoglobulin G (IgG) fractions obtained
from rabbit preimmune and rabbit antipeptide sera were used to corroborate
findings first obtained with the rabbit sera. The purification of IgG fractions from
rabbit sera was achieved by ammonium sulfate precipitation of serum to obtain
the Ig fraction followed by ion-exchange chromatography on an Econo-Pac Ig
purification column (Bio-Rad Laboratories, Richmond, Calif.) as per instruc-
tions supplied by the manufacturers. Briefly, the prepacked column was exten-
sively washed with regeneration buffer (1.5 M sodium thiocyanate) and equili-
brated with application buffer (0.02 M Tris-HCl, pH 8.0, containing 0.028 M
NaCl). The Ig fraction of serum preequilibrated with the application buffer was
applied to the column and IgG was eluted with the application buffer. The
absorbance at 280 nm of each fraction was determined, and fractions with an
optical density (OD) of $0.1 were pooled and dialyzed against 200 volumes of
PBS (0.15 M, pH 7.2). The purity of this preparation was ascertained by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immuno-
blotting.
In still another experiment, immune IgG was isolated from the test sera by
immuno-affinity chromatography. An immunoadsorbent column was prepared by
coupling 18-mer (dissolved in 0.1 M NaHCO3 buffer, pH 8.3, containing 0.5 M
NaCl) to the cyanogen bromide-activated Sepharose 4B matrix (Pharmacia Fine
Chemicals, Uppsala, Sweden), and its uncovered reactive sites were blocked with
ethanolamine. The purified IgG fraction obtained after ion-exchange chroma-
tography of rabbit anti-18-mer serum was applied to the immunoadsorbent
column, extensively pre-washed, and equilibrated with PBS containing Tween-20
(0.2%, vol/vol). The peptide-specific antibody was eluted with glycine-HCl buffer
(0.1 M, pH 2.5), and the fractions were neutralized by addition of Tris base (2.0
M). The fractions were pooled and characterized as described above for the
ion-exchange chromatography.
ELISA. The wells of flat-bottomed Immulon-2 plates (Dynatech) were coated
with an appropriate concentration of the capture antigen (carrier-free 18-mer,
nonapeptide-TT conjugate, the whole parasite lysate, or each of the six recom-
binant TRAP constructs) in 0.06 M carbonate-bicarbonate buffer, pH 9.6. The
uncovered reactive sites in the wells were blocked with a 5% solution of milk
powder in PBS. The antigen-coated wells were sequentially incubated with serial
dilutions of test sera and an optimally diluted enzyme-labeled second antibody
(horseradish peroxidase-labeled anti-rabbit IgG). In between these incubations,
plates were washed with a 0.05% solution of Tween-20 in PBS. The enzyme
reaction was developed biochemically with H2O2 as the enzyme substrate and
ortho-phenylenediamine dihydrochloride as the chromogen; the reaction was
stopped with 8 N H2SO4, and the OD490 of the reaction product in the wells was
recorded with a Bio-Tek microplate reader.
Immunoblotting. Having ascertained the reactivity of the antipeptide antibody
in ELISA, we used this antibody to probe the whole parasite lysate, which had
been fractionated by SDS-PAGE and transferred onto nitrocellulose paper by
standard procedures. The recombinant fragments of TRAP, viz., TRAP 1.1, 1.2,
1.3, 1.4 (all containing the conserved sequence motif), and 1.5 (lacking the
conserved motif) (25), were also studied for their reactivity with the antipeptide
sera by immunoblotting. The parasite proteins and the recombinant TRAP
constructs, separated by SDS-PAGE and transferred onto a nitrocellulose paper,
were incubated first with the rabbit antiparasite serum or antipeptide sera or with
the affinity-purified immune IgG and then with the horseradish peroxidase-
labeled anti-rabbit IgG antibodies. The final enzyme reaction was developed with
4-chloro-1-naphthol as the chromogen and H2O2 as the substrate.
Immunofluorescence assay. The rabbit antipeptide sera were also tested, in an
immunofluorescence assay, for their reactivity with the authentic parasite pro-
tein(s). The assay was performed essentially as described earlier (34). Briefly,
multispot antigen slides were made from a P. falciparum (FID-3 isolate)-infected
erythrocyte suspension prepared from an asynchronous culture of the parasite.
The antigen spots on the slides were air dried and fixed with an acetone-
methanol (90:10, vol/vol) mixture at 2208C for 40 min. The antigen spots were
sequentially incubated with serially diluted test sera and optimally diluted fluo-
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rescein isothiocyanate-labeled secondary antibody with the excess reactants
washed off after each incubation. The slides were examined under a fluorescence
microscope (Wild Leitz GmbH, Wetzlar, Germany) by alternately using visible
and UV light to see the specific binding of antibody to the parasite.
Merozoite invasion inhibition and parasite growth inhibition assays. For the
merozoite invasion inhibition assay, cultures of the FID-3 isolate of P. falciparum
were synchronized by two treatments with 5% sorbitol (22) and incubated for
about 30 h so that at the time the assay was set up, more than 95% of the
parasites were late trophozoites. The assay cultures were then set up with normal
or immune rabbit serum incorporated in the culture medium and incubated in a
candle jar at 378C for 20 h (the 20-h assay). At the end of the period, a smear
from each culture well was drawn and stained with Giemsa for recording para-
sitemia by microscopy; only the ring-infected erythrocytes were counted as par-
asitized cells for calculating percent parasitemia. In a subsequent experiment,
various concentrations of purified IgG fractions isolated from the preimmune or
immune rabbit sera were incorporated in the test system.
For the parasite growth inhibition assay, cultures were grown in RPMI-1640
medium supplemented with 10% human blood group AB/Rh1 serum plus 0.5 to
5.0% normal (preimmune) or immune rabbit serum or various concentrations of
different synthetic peptide constructs. The cultures were incubated for 72 h (the
72-h assay) in a candle jar at 378C.
Percent inhibition of growth or merozoite invasion was calculated as 100 2
[(% parasitemia in test/% parasitemia in control) 3 100]. The results of the
parasite growth inhibition assays were analyzed by using Student’s t test.
RESULTS
Immunogenicity of the synthetic peptides. Immunization of
rabbits with the carrier-free 18-mer (100 mg per animal) or
nonapeptide in CFA and two booster injections with the re-
spective peptide in IFA did not induce any detectable level of
the peptide-specific antibody response (data not presented).
One of the two rabbits immunized with the 18-mer–TT conju-
gate mounted a boostable, IgG antibody response directed
against the peptide, as measured in an ELISA. Figure 1 rep-
resents the kinetics of the peptide-specific antibody response
elicited by the 18-mer–TT conjugate. The preimmune serum
(1/400 dilution) yielded an ELISA OD490 of 0.06, while the test
(day 42) serum from the same rabbit gave an OD490 of 2.5.
This antiserum or its purified immune IgG fraction was used in
subsequent assays, viz., immunoblotting of the parasite pro-
teins or recombinant TRAP constructs, immunofluorescence,
and parasite growth inhibition assays, etc. Rabbits immunized
with the nonapeptide-BSA conjugate also made a boostable,
IgG-type antibody response directed against the nonapeptide,
as measured in an ELISA with the nonapeptide-TT conjugate
as the capture antigen. The preimmune sera (1/100 dilution) of
two rabbits, immunized with nonapeptide-BSA, yielded OD490
values of 0.08 and 0.09, respectively, while the test (day 42)
sera from the same rabbits gave corresponding values of 0.78
and 1.123, respectively. The end point titers of the test sera
were 1/10,000 or higher, at which dilution the ELISA OD value
FIG. 1. Time course of anti-18-mer antibody response as monitored by
ELISA, with 18-mer as the capture antigen. The rabbit was either immunized
with 18-mer–TT conjugate emulsified with CFA and IFA (Test) or injected with
the adjuvants alone (Control). Each serum sample was diluted 1/400 and each
datum point is an average of OD values obtained in duplicate wells.
FIG. 2. Specificity of rabbit anti-18-mer antibody. The preimmune and test sera were diluted 1/1,000 and tested in an antibody-binding ELISA with various TRAP
constructs as capture antigens. 9-mer and 18-mer, synthetic peptides; 1.0 to 1.5, recombinant TRAP constructs; PfAg, whole parasite lysate antigen.
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was more than twice the OD obtained with the preimmune
sera (diluted 1/100). Immune IgG purified from the test serum
of one of these animals was used in the merozoite invasion
inhibition assay as described below.
Cross-reactivity of the antipeptide serum with the recombi-
nant TRAP constructs and the parasite protein(s). The results
of an ELISA to characterize the specificity of the anti-18-mer
antibody are presented in Fig. 2. We found that of the six
recombinant constructs, namely, TRAP 1, TRAP 1.1, TRAP
1.2, TRAP 1.3, TRAP 1.4, and TRAP 1.5, as well as the whole
parasite lysate used as an antigen, TRAP 1.3, which contains
the entire 18-mer sequence and a stretch of 26 additional
residues at the carboxyl terminus, bound the maximum amount
of rabbit anti-18-mer antibody, as an apparent from the ratio of
ELISA OD values obtained with the test serum and the cor-
responding preimmune serum (both diluted 1/1,000). In con-
trast, no detectable levels of the anti-18-mer antibody bound to
TRAP 1.5, which completely lacks the conserved motif but has
almost the entire amino-terminal sequence of the protein in-
tact. Clearly, the rabbit anti-18-mer antibody is specifically
directed against the conserved motif sequence of TRAP. Our
results presented above indicated that the synthetic peptides
could generate a specific antibody response, but in order to
determine whether the response would be of any value against
the pathogen, it would be important to ascertain if the anti-
18-mer serum recognized the parasite protein, a positive result
indicating that the synthetic construct faithfully represented
the authentic parasite protein structure. We found that this
antibody, indeed, cross-reacted with the parasite protein in
different assays. In an immunoblot experiment, we found that
this antibody reacted very strongly with a parasite protein with
an apparent molecular mass of approximately 78 kDa (Fig.
3A). Similar reactivity was obtained with the affinity-purified
antibody as well; more significantly, rabbit anti-18-mer serum
depleted of antipeptide antibody by incubation with 18-mer
immobilized on a Sepharose 4B matrix failed to reveal any
FIG. 3. (A) Immunoblot of P. falciparum lysate with the rabbit antipeptide serum. The parasite antigens were separated on an 8% acrylamide gel by SDS-PAGE
and electroblotted onto nitrocellulose paper before being probed with preimmune sera (lanes 1 and 3), antiparasite serum (lane 2) and antipeptide (18-mer) serum
(lane 4). Prestained molecular mass markers (SDS-7B; Sigma) to indicate electrophoretic migration are on the left. (B) Immunoblot of P. falciparum lysate probed with
the affinity-purified, 18-mer-specific, rabbit IgG. The parasite proteins were separated as described above and probed with antipeptide (18-mer) serum (lane 1),
affinity-purified IgG fraction from the same serum (lane 2), the same serum but depleted of antipeptide antibody (lane 3), and a rabbit antiparasite serum (lane 4).
Prestained molecular mass markers (SDS-7B; Sigma) are on the right. Arrows indicate the 78-kDa protein.
FIG. 4. Immunoblot showing cross-reactivity of the antipeptide serum with the recombinant TRAP constructs. The whole parasite lysate proteins (lane 1) and the
recombinant TRAP constructs 1.1 to 1.5 (lanes 2 to 5, respectively) were separated on an 8% polyacrylamide gel by SDS-PAGE and either stained with Coomassie
blue (A) or blotted with the antipeptide (18-mer) serum (B). Molecular mass markers (SDS-6H in panel A and SDS-7B in panel B; Sigma) are on the left side of each
panel.
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parasite protein in the immunoblots (Fig. 3B). Furthermore,
the recombinant fragments of TRAP (TRAP 1.1, 1.2, and 1.3)
containing the conserved motif were distinctly recognized by
this antibody (Fig. 4, lanes 2, 3, and 4, respectively); in contrast,
the same anti-peptide serum showed no reactivity with the
recombinant fragment of TRAP (TRAP 1.5) which lacks the
conserved motif (Fig. 4, lanes 6). Surprisingly, TRAP 1.4,
which contains the conserved nonapeptide sequence at its car-
boxyl terminus, did not show any positive result in this immu-
noblot (Fig. 4, lanes 5). The preimmune serum from the same
rabbit consistently gave a negative result in immunoblots of the
whole parasite lysate and the recombinant constructs (results
not presented). Both preimmune and test sera had been pread-
sorbed with fresh human erythrocytes and with E. coli bacterial
lysate to obviate the possibility of nonspecific interactions in all
of the assays described above.
Immunological reactivity of the antipeptide serum with the
parasite protein was further corroborated by the results we
obtained with the immunofluorescence assay (Fig. 5). We ob-
served a generalized fluorescent staining of the late trophozo-
ites of P. falciparum in this assay. The preimmune serum
showed no reactivity with the parasite or with the parasitized
erythrocyte.
Merozoite invasion inhibitory and parasite growth inhibi-
tory activities of peptide-specific antibody. Our initial experi-
ments to grow P. falciparum in the medium containing 10%
normal rabbit serum, instead of human serum, were not suc-
cessful (unpublished data). However, addition of up to 5.0%
normal rabbit serum to the cultures growing normally in the
medium with 10% human serum did not affect the rate of
growth of parasites. Thus, when P. falciparum was cultured in
complete medium supplemented with normal rabbit sera in
concentrations ranging from 0.5 to 5.0%, the levels of para-
sitemia obtained after 72 h at various concentrations were
comparable; from an initial concentration of 0.5% normal rab-
bit serum at 0 h, the parasitemia recorded at 72 h ranged from
6.97 to 7.20%, with an average of 7.1% 6 0.09% (mean 6
standard deviation). However, incorporation of as little as
0.5% rabbit antinonapeptide (the most conserved sequence in
TRAP) serum caused a 26% inhibition (P , 0.01) of the
parasite growth in a span of 72 h. With the concentration of
immune serum raised to 5.0%, we found that the inhibition of
growth increased to almost 50 percent (Table 1). Comparable
results were obtained with the rabbit anti-18-mer serum as well
(Table 1). In contrast, antiserum from a rabbit immunized with
the P-8 MSP-1 peptide exerted only a marginally adverse effect
on the growth of parasites in this assay; at the end of a 72-h
growth inhibition assay, levels of parasitemia obtained in the
presence of 5.0% preimmune and immune sera from this rab-
bit were 7.1 and 6.12%, respectively. This amounted to merely
a 14% inhibition of the parasite growth, which was statistically
insignificant (Table 1).
In order to establish further that the inhibitory effect of the
serum was due to antibodies, we tested the purified IgG frac-
tion isolated from the anti-nonapeptide serum for its effect on
the merozoite invasion of erythrocytes in the 20-h assay. Re-
sults of this assay, presented in Fig. 6, clearly indicated that the
immune rabbit IgG could inhibit the merozoite invasion in a
dose-dependent manner, while the normal (preimmune) rabbit
IgG had no significant effect. Thus, a nearly 50% inhibition of
invasion was obtained with a 300-mg/ml concentration of pu-
rified immune IgG while almost complete inhibition was
achieved with a 1.2-mg/ml concentration of immune IgG.
The 18-mer, which readily dissolved in the culture medium,
was also tested for its potential to inhibit the merozoite inva-
sion of erythrocytes in vitro in the 20-h assay. This experiment
was repeated at least five times with reproducible results. Re-
sults from one representative experiment are presented in Ta-
ble 2. At the end of the 20-h assay, the parasitemia (only
FIG. 5. Immunofluorescent staining of the trophozoites of P. falciparum with the antipeptide serum. (A) Parasites showing bright fluorescent staining under UV
light. (B) The same field under visible light showing the parasite-infected erythrocyte with a late trophozoite and dark hemozoin pigment bodies; some uninfected
erythrocytes can also be seen.
TABLE 1. In vitro growth of P. falciparum in the presence of
preimmune and immune sera from rabbits immunized with
nonapeptide, 18-mer, or P-8a
Peptide
Serum
concn
(%)
% Parasitemiab
%
InhibitionPreimmune
serum
Immune
serumc
9-mer 0.5 6.97 6 0.21 5.15 6 0.15* 26.20
1.0 7.10 6 0.04 4.60 6 0.10* 35.22
2.5 7.20 6 0.20 4.20 6 0.30* 41.70
5.0 7.20 6 0.60 3.75 6 0.02* 48.00
18-mer 0.5 NDd 4.65 6 0.03* 23.18
1.0 ND 3.656 0.07* 39.70
2.5 ND 3.526 0.02* 41.85
5.0 6.05 6 0.02 2.87 6 0.04* 52.59
P-8 5.0 7.10 6 0.35 6.12 6 0.58 13.80
a Parasitemia at 72 h is presented; initial parasitemia was 0.51%.
b Data are means 6 standard deviations of the results obtained in triplicate
wells for each category of serum concentration.
c The effect of P-8 was statistically insignificant; all other results were signifi-
cant at P ,0.01 by Student’s t test.
d ND, not determined.
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ring-infected cells) in the normal control wells was 3.6% 6
0.09% and was within the normal limits of growth. However,
the 18-mer, when incorporated at concentrations ranging from
25 to 200 mM in the culture medium, caused an approximately
25 to 50% inhibition of the merozoite invasion, respectively,
compared with the controls (Table 2). The levels of inhibition
were considerably lower when we used the 18-mer analog in
which the conserved cysteine residues were protected and,
therefore, not available as free sulfhydryls as in the 18-mer
(Table 2). Another peptide, P-8, exerted an inhibitory effect to
a maximum of only 15.84% even when used at a concentration
of 200 mM (Table 2).
DISCUSSION
The most important finding of this study is the demonstra-
tion of a TRAP-like protein in the asexual blood stages of the
parasite, which was fractionated by SDS-PAGE and immuno-
blotted with the rabbit anti-18-mer serum. The apparent mo-
lecular mass of the parasite protein recognized in these immu-
noblots was estimated to be 78 kDa (Fig. 3), which is higher
than that estimated from the deduced amino acid sequence of
the P. falciparum TRAP (;63.3 kDa) (29). In fact, it is known
for several malarial proteins that because of the preponder-
ance of hydrophobic residues in these proteins, their apparent
molecular weights do not conform to the predicted molecular
weights (1). Further corroboration of our finding that the par-
asite protein seen in our immunoblot indeed represents a
TRAP-like protein comes from our observation that the anti-
peptide serum bound specifically to the recombinant TRAP
constructs (TRAP 1.1, TRAP 1.2, and TRAP 1.3) containing
the conserved motif, WSPCSVTCG, and not to the construct
that did not contain this motif (TRAP 1.5), clearly establishing
the immunological specificity of the test serum (Fig. 4). In the
immunofluorescence assay also, the antipeptide antibodies re-
acted strongly with the trophozoites of P. falciparum (Fig. 5),
while the preimmune serum from the same experimental ani-
mal consistently yielded a negative reaction. Robson and col-
leagues (29) have demonstrated TRAP-specific mRNA in the
parasitized erythrocytes, and they later demonstrated the pres-
ence of this protein in both sporozoites and trophozoites by
immunofluorescence assay (12). Our findings presented in Fig.
3 to 5 provide evidence for the expression of a TRAP-like
protein during the erythrocytic cycle of the parasite.
The results that we obtained in ELISAs regarding the reac-
tivity of the anti-peptide (18-mer) serum with various recom-
binant TRAP constructs (Fig. 2) deserve further discussion,
besides providing additional evidence for the specificity of the
antibody. While, predictably, we observed no detectable reac-
tivity with the construct TRAP 1.5 (residues 26 to 204), rep-
resenting almost the entire region of the protein from the
amino terminus to the conserved motif, we obtained the high-
est level of reactivity with TRAP 1.3 (residues 26 to 299), which
includes the 18-residue conserved motif (residues 249 to 266)
and, more importantly, a stretch of another 33 residues con-
taining two cysteines, towards the carboxyl terminus. Interest-
ingly, the levels of ELISA reactivity with the whole parasite
lysate, as well as with other constructs containing the nonapep-
tide conserved motif (residues 250 to 258), were lower than
that obtained with TRAP 1.3 by more than an order of mag-
nitude (Fig. 2). Thus, of all the recombinant constructs used in
this study, TRAP 1.3 (residues 26 to 299) seems to present the
target epitope of this antibody in the most appropriate confor-
mation. This observation was further supported by the results
of the immunoblot experiment presented in Fig. 4. It is inter-
esting that the construct TRAP 1.4 (residues 26 to 273), which
has the most conserved nonapeptide sequence at close prox-
imity to its carboxyl terminus ending with a cysteine, showed
almost no reaction with the antipeptide antibody in the immu-
noblot, underlining the crucial role of amino acid residues 274
to 299 in providing appropriate conformation to the target
epitope. It seems pertinent to recall that Ballou and colleagues
(2) had also observed that antibodies raised against the region
RII peptide, with the amino acid sequence TEWSPCS
VTCGNGIQ (the conserved TRAP motif is indicated in bold
letters), of the CS protein of P. falciparum did not recognize
the intact CS protein in the immunofluorescence and immu-
noblot assays. In fact, in our studies, TRAP 1.3 has proved to
be more immunoreactive than even the putative TRAP-like
parasite protein. This might be something similar to what
FIG. 6. Inhibition of the merozoite invasion of human erythrocytes by the
rabbit antinonapeptide IgG. Data are percents inhibition of invasion observed in
the 20-h assay calculated from parasitemias obtained in the presence of preim-
mune (Normal IgG) and the corresponding immune (Immune IgG) sera purified
by ion-exchange chromatography. Each datum point is an average of triplicate
values. % parasitemia at 0 h was 0.37; % parasitemia in control serum at 20 h was
1.53.
TABLE 2. Inhibitory effect of 18-mer on P. falciparum merozoite
invasion of human erythrocytesa
Peptide Concn(mM)
%
Parasitemiab
(rings only)
%
Inhibition
None Nil 3.60 6 0.09 0.00
18-mer 25 2.65 6 0.05* 26.39
50 2.40 6 0.00* 33.34
100 2.18 6 0.01* 39.56
200 1.77 6 0.03* 50.84
18-mer (Cys protected) 25 3.36 6 0.10 6.70
50 3.22 6 0.06 10.56
100 2.95 6 0.06 17.87
200 2.91 6 0.03 19.07
P-8 200 3.03 6 0.39 15.84
a Parasitemia at 20 h is presented; initial parasitemia was 0.85%.
b See Table 1, footnote b. *, P , 0.01 by Student’s t test.
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Wrightsman and colleagues (37) have reported for the trypo-
mastigote surface antigen-1 protein of Trypanosoma cruzi. The
cleavage of trypomastigote surface antigen-1 protein in the
form of recombinant amino-proximal and carboxyl-proximal
constructs was found to unmask a protective epitope which
otherwise remained cryptic and immunologically inaccessible
in the intact protein. The observations of Ballou and col-
leagues (2) and the results of our present study provide a
reasonable basis for further investigation of the importance of
amino acid residues 274 to 299 in determining the antigenicity
of TRAP and its possible role in the parasite-host cell inter-
action.
The second important finding of this study is that rabbit
antibodies raised against as short a sequence as a nonapeptide
present in an asexual blood stage protein of P. falciparum can
exert a strong parasiticidal effect (Table 1; Fig. 6). As far as
immunity to the asexual blood stages is concerned, Brown (3)
has argued that antibodies appear to be important in providing
specific protection to the host, as also demonstrated earlier by
Cohen and colleagues in their classical studies of children in
the Gambia (11). Others have shown that antibodies from
immune monkeys and humans can inhibit in vitro growth of the
parasite as well as protect naive recipients (10, 28, 35). There
is no information in the literature about the putative protective
potential of TRAP or TRAP-like protein against the asexual
blood stages of the malaria parasite. However, in another sys-
tem, namely, P. yoelii in mice, immunization of animals with a
mixture of CS protein and sporozoite protein SSP-2, which is
an analog of TRAP, was found to impart protection to mice
against a sporozoite challenge (20). Interestingly, immuniza-
tion with CS protein or SSP-2 alone induced protection in only
a small proportion of animals. It was also established in that
study that cytotoxic T lymphocyte responses played a critical
role in protection against the sporozoite challenge. These re-
sults of Khusmith and colleagues (20) with SSP-2, and our
results with the TRAP motif that antibodies to this motif can
inhibit in vitro merozoite invasion of erythrocytes (Table 1;
Fig. 6), indicate that an appropriate immune response to
TRAP might prove effective against two different stages of the
parasite. Even though it required a relatively high concentra-
tion (1.2 mg/ml) of immune IgG to achieve a nearly total
inhibition of the merozoite invasion (Fig. 6), the dramatic
decline in parasitemia obtained with this antibody implies that
an appropriate immune response elicited with a synthetic im-
munogen might help to reduce the parasite load in vivo, thus
alleviating the severity of infection.
Our observation that the synthetic construct, i.e., the 18-mer,
which contains the nonapeptide sequence, caused significant
inhibition of the merozoite invasion of erythrocytes suggests
that this motif, along with some other such motifs, might be
involved in some vital biological process(es) of the parasite. As
mentioned earlier, this sequence is also present in the CS
protein of all Plasmodium species sequenced so far as well as
in SSP-2 of P. falciparum and P. yoelii (30, 31). Such wide-
spread occurrence of this motif in these parasite proteins
strengthens the contention about its potential role in the biol-
ogy of the parasite. Since this motif is also present in throm-
bospondin and properdin, the cell adhesive molecules involved
in cell-cell interaction, it is reasonable to speculate that in the
malaria parasite, this molecule, and particularly the motif
around the WSPCSVTCG sequence, may also play some im-
portant role in the parasite-host cell interaction, especially in
the process of invasion of hepatocytes by sporozoites and of
erythrocytes by merozoites. In fact, Cerami and colleagues (4)
have demonstrated that recombinant constructs representing
the CS protein of P. falciparum and containing the WSPCS
VTCG motif can bind to human hepatocytes and specifically
inhibit invasion by sporozoites, whereas a construct without
this motif, but with all other features of the CS protein intact,
does not do so. More recently, Muller and coworkers (25) have
reported similar findings with recombinant fragments of TRAP
of P. falciparum. Subsequently, Robson and colleagues (28a)
have observed that the expression of TRAP in sporozoites is
concomitant with the formation of micronemes and the devel-
opment of sporozoite infectivity. These findings lend support
to the suggestion that TRAP is one of the critical parasite
molecules involved in the sporozoite invasion of hepatocytes.
We believe that a similar binding of TRAP-like protein to
erythrocytes is quite likely to occur as part of the process of
invasion. We have obtained a significant level of inhibition of
the merozoite invasion of erythrocytes with the 18-mer. In
order to rule out the possibility of a nonspecific toxic effect of
the synthetic construct, we preincubated normal erythrocytes
with the 18-mer for 24 h and then washed off the excess of the
peptide. These cells remained fully susceptible to merozoite
invasion and supported normal parasite growth (data not pre-
sented). We also found that a modified analog of the 18-mer in
which the cysteine side-chain sulfhydryl groups were protected
and a 21-mer malaria peptide (P-8) containing a cysteine res-
idue, both of which were synthesized and purified in our lab-
oratory by essentially the same procedures, inhibited the mer-
ozoite invasion to almost insignificant levels (Table 2). This
further lends support to our contention that the inhibition of
merozoite invasion obtained with the 18-mer was specific in
nature. From our observation that the 18-mer peptide inhibits
the parasite growth in a dose-dependent manner, it may still be
hypothesized that the conserved-motif peptide somehow com-
petes with the blood stage parasite (merozoite) in the initial
interaction with some receptor(s) on the erythrocyte.
The observation that carrier-free nonapeptide and 18-mer
did not induce antibodies in rabbits or mice lends support to
results of previous studies indicating poor immunogenicity of
synthetic peptides (2, 7, 8, 21). In sera collected from clinical
cases of P. falciparum malaria, we obtained much lower levels
of antibodies reactive against the nonapeptide or the 18-mer
(unpublished observations), although all of these sera har-
bored high levels of malaria antibodies as measured in an
ELISA with the whole parasite lysate as well as two other
synthetic antigens representing B-cell determinants of MSP-1
of P. falciparum (21). Once again, this underscores the problem
of poor immunogenicity of malaria peptides in general and of
putatively protective epitopes in particular. With the delinea-
tion of “universal” Th cell determinants in the parasite protein,
the problem of genetic restriction of immune response to pep-
tide immunogens might be addressed with some measure of
success (21). For enhancing the immunogenicity of synthetic
peptides, it will be necessary to devise a strategy which facili-
tates appropriate presentation of these molecules to the im-
mune system. It can be argued that the poor immunogenicity of
the TRAP motif may partly be due to its being a part of
self-molecules like thrombospondin and properdin, etc., and
that induction of an immune response to this motif is poten-
tially fraught with inducing autoimmune responses, as has been
shown for the hsp-70 cognate parasite protein (23). On the
other hand, several other P. falciparum proteins, viz., Pfs25,
MSP-1, and p41 (aldolase), contain sequences homologous to
those of host proteins such as the epidermal growth factor (18),
the intermediate filament protein (8), and the human aldolase
enzyme (5), respectively; significantly, none of these sequences
have been shown to induce or be the target of any autoimmune
response. Studies are under way to investigate these aspects of
possible autoimmune response to the 18-mer motif as well as
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the potential of this motif to impart protection to mice against
challenge infection with P. yoelii.
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